Frequently Asked Questions
What is the CAMONX CheC test?
It is a new non-invasive test for prostate cancer.
The test monitors the chemical composition of seminal fluid, which significantly changes in the presence of prostate cancer.
What is the current status of test development?
Cambridge Oncometrix conducted a pilot clinical trial abroad.
In September 2019, we launched a clinical study in the UK.
The results of this multi-centre study termed PLiS and led by the University College London will be used to seek regulatory approvals of the clinical test in the UK and EU.
Can CAMONX ChEC test replace biopsy?
A needle biopsy remains the ultimate diagnostic test for prostate cancer.
However, CheC test may allow a patient to forgo an invasive prostate biopsy procedure where it is highly unlikely to be positive.
Is the CAMONX CheC test protected by a patent?
Cambridge Oncometrix technology is protected by the patents in the US and EU countries.
How did we discover the tumour markers?
Cambridge Oncometrix discovered a panel of substances (biomarkers) present in the prostate, which significantly change when cancer is present in the gland.
The biomarkers were identified in a direct comparison of the very carefully characterized prostate tissue samples taken from healthy men and men with benign prostatic hyperplasia (BPH) or prostate cancer.
Biomarkers were identified in a direct comparison of the very carefully characterized prostate tissue samples taken from:
- healthy men
- men with Benign Prostatic Hyperplasia
- men with Prostate Cancer
Can I participate in the current study?
You may be able to join the current clinical trial if you have been referred for a prostate biopsy to UCLH, Leeds NHS Teaching Hospital, or Norwich Hospital (NNUHFT).
Can the CAMONX CheC test predict aggressiveness and size of the prostate cancer?
It is unknown yet.
We believe there is a correlation between Oncometrix biomarkers and the aggressiveness of the tumour.
Our current study shall answer this question.